{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:14:33Z","timestamp":1767212073137,"version":"3.41.2"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Given the lack of evidence and guideline-based recommendations on the best preoperative oral anticoagulation (OAC) management strategies for transcatheter aortic valve implantation (TAVI), this study aims to compare continued oral anticoagulation (cOAC) versus interrupted oral anticoagulation (iOAC) strategies. We conducted a comprehensive search across PubMed, Embase, Cochrane Central, and ClinicalTrials.gov from inception till February 2025 for studies comparing periprocedural cOAC or iOAC in patients undergoing TAVI. Outcomes were analyzed using a random-effects model to pool odds ratios (ORs) with 95% confidence intervals (CIs). Four studies, comprising a total of 3117 patients, were included in the final analysis. The early (30-day) safety outcome and composite ischemic events were comparable between the approaches. There was no significant difference between cOAC and iOAC in terms of any bleeding, major bleeding, or life-threatening bleeding. However, cOAC was associated with a slightly higher incidence of minor bleeding events (OR: 1.40, 95% CI: 1.02\u20131.93, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04). Additionally, major vascular complications, all-cause mortality, cardiac-specific mortality, stroke, transient ischemic attack, myocardial infarction, and length of hospital stay were comparable between the 2 strategies. Both cOAC and iOAC approaches demonstrated comparable outcomes, with cOAC being associated with a slightly higher incidence of minor bleeding events.<\/jats:p>","DOI":"10.1097\/crd.0000000000001005","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T04:01:13Z","timestamp":1754020873000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Continued Versus Interrupted Oral Anticoagulation During Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis"],"prefix":"10.1097","author":[{"given":"Farhan","family":"Naeem","sequence":"first","affiliation":[{"name":"From theDepartment of Cardiology, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehroze","family":"Tabassum","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Saad","family":"Rakab","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mansoura University, Mansoura, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Farid","family":"Gadelmawla","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Menoufia University, Menoufia, Egypt"},{"name":"Medical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aroma","family":"Naeem","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timir K.","family":"Paul","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center at Nashville, Ascension St. Thomas Hospital, Nashville, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"R1-20250801","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2022.05.002","article-title":"Evolving concepts in the management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation.","volume":"101","author":"van Ginkel","year":"2022","journal-title":"Eur J Intern Med"},{"key":"R2-20250801","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.jcin.2017.04.034","article-title":"Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement.","volume":"10","author":"Piccolo","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"R3-20250801","first-page":"1285","article-title":"Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome.","volume":"38","author":"Tarantini","year":"2017","journal-title":"Eur Heart J"},{"key":"R4-20250801","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American College of Chest Physicians Clinical Practice Guideline.","volume":"162","author":"Douketis","year":"2022","journal-title":"Chest"},{"key":"R5-20250801","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jacc.2022.11.050","article-title":"Bleeding events after transcatheter aortic valve replacement: JACC state-of-the-art review.","volume":"81","author":"Avvedimento","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R6-20250801","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R7-20250801","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4244\/EIJV8I7A121","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.","volume":"8","author":"Kappetein","year":"2012","journal-title":"EuroIntervention"},{"key":"R8-20250801","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jcin.2020.09.062","article-title":"Safety and efficacy of transcatheter aortic valve replacement with continuation of Vitamin K antagonists or direct oral anticoagulants.","volume":"14","author":"Brinkert","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"R9-20250801","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa2407794","article-title":"Continuation versus interruption of oral anticoagulation during TAVI.","volume":"392","author":"van Ginkel","year":"2025","journal-title":"N Engl J Med"},{"key":"R10-20250801","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.amjcard.2018.12.042","article-title":"Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implantation and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation.","volume":"123","author":"Mangner","year":"2019","journal-title":"Am J Cardiol"},{"key":"R11-20250801","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.amjcard.2021.03.022","article-title":"Pre-operative continued oral anticoagulation impact on early outcomes after transcatheter aortic valve implantation.","volume":"149","author":"Tagliari","year":"2021","journal-title":"Am J Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T04:01:15Z","timestamp":1754020875000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":11,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001005","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}